← FDA DRUG APPROVALS

FDA NDA · NDA213436

TRUDHESA

dihydroergotamine mesylate

Sponsor: IMPEL PHARMS

APPLICATION
NDA213436
TYPE
NDA
ORIGINAL APPROVAL
2021-09-02
LATEST ACTION
2021-09-02
ROUTE
NASAL
DOSAGE FORM
SPRAY, METERED
MARKETING STATUS
Prescription

Products

TRUDHESA · ReferencePrescription
DIHYDROERGOTAMINE MESYLATE 0.725MG/SPRAY · SPRAY, METERED · NASAL

Approval history

2021-09-02Type 5 - New Formulation or New Manufacturer · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →